Home › Companies › Esperion Therapeutics, Inc. › 2024-2025

Esperion Therapeutics, Inc. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and Esperion Therapeutics, Inc.’s Form 8-K, filed June 2, 2025 (Item 5.07 on EDGAR). Page generated October 25, 2026.

6Reported items
146Asset managers
679Fund votes
May 29, 2025Meeting date

Results at a glance

Meeting of May 29, 2025: 5 items on Esperion Therapeutics, Inc.’s Form 8-K, filed June 2, 2025: 5 without a stated outcome.

Material dissent

Elect Director: Jay P. Shepard 77% of votes cast Outcome not stated Director under 80%
The Company's stockholders approved Proposal 2. 73% of votes cast Outcome not stated Under 80%
The Company's stockholders approved Proposal 4. 77% of votes cast Outcome not stated Under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Esperion Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by Esperion Therapeutics, Inc.

These tallies are Esperion Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 2, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Esperion Therapeutics, Inc. — official shareholder meeting results, meeting held May 29, 2025
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Jay P. Shepard	75,821,767	--	--	23,071,427	37,575,467	77%	Not verified	—
Elect Director: Seth H.Z. Fischer	83,336,719	--	--	15,556,475	37,575,467	84%	Not verified	—
The Company's stockholders approved Proposal 2.	70,756,440	26,653,578	1,483,176	--	37,575,467	73%	Not verified	—
The Company's stockholders approved Proposal 3.	118,152,430	16,130,318	2,185,913	--	--	88%	Not verified	—
The Company's stockholders approved Proposal 4.	75,390,791	22,685,588	816,815	--	37,575,467	77%	Not verified	—

Source: Esperion Therapeutics, Inc., Form 8-K, filed with the SEC on June 2, 2025 — read the filing on EDGAR.

How asset managers voted at the Esperion Therapeutics, Inc. 2024-2025 meeting

Each item below shows how the 146 asset managers that disclosed a Esperion Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Esperion Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Elect Director: Jay P. Shepard

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

77% Majority: yes · of votes cast

FOR 77%WITHHELD

FOR: 75,821,767WITHHELD: 23,071,427

Details: description as filed, official tally, votes by 36 asset managers

Description as filed by funds: Election of Class II Directors: Jay P. Shepard

Esperion Therapeutics, Inc.’s own tally for this item (“Elect Director: Jay P. Shepard”): 75,821,767 for, 23,071,427 withheld, per its Form 8-K filed June 2, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 77% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 23,906,982 for, 2,053,572 withheld.

FOR

FOR: 23,906,982WITHHOLD: 2,053,572

Largest asset managers voting on “Election of Class II Directors: Jay P. Shepard” at Esperion Therapeutics, Inc., 2024-2025
Asset manager	For	Withheld	Vote
WASATCH FUNDS TRUST	8,264,814	0	For
Vanguard	7,711,521	0	For
Fidelity	3,702,644	0	For
BlackRock	3,347,621	0	For
TIAA	0	794,539	Withhold
Charles Schwab	0	431,527	Withhold
Equitable	54,212	159,260	Mixed
State Street	531	185,958	Withhold
Invesco	0	162,539	Withhold
ETFis Series Trust I	140,800	0	For
Lincoln Financial	0	140,100	Withhold
Northern Trust	0	90,862	Withhold
ProShares	89,094	0	For
Pacific Life	84,096	0	For
AIG/SunAmerica	79,571	0	For
Bridge Builder Trust	71,755	0	For
John Hancock	67,549	0	For
Voya	0	52,766	Withhold
Brighthouse	43,205	0	For
Direxion Shares ETF Trust	40,608	0	For
Blackstone Alternative Investment Funds	40,100	0	For
Jacob Funds Inc.	31,497	0	For
SEI	31,100	0	For
DWS	29,757	0	For
Global X	29,749	0	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

2. Elect Director: Seth H.Z. Fischer

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

84% Majority: yes · of votes cast

FOR 84%WITHHELD

FOR: 83,336,719WITHHELD: 15,556,475

Details: description as filed, official tally, votes by 36 asset managers

Description as filed by funds: Election of Class II Directors: Seth H.Z. Fischer

Esperion Therapeutics, Inc.’s own tally for this item (“Elect Director: Seth H.Z. Fischer”): 83,336,719 for, 15,556,475 withheld, per its Form 8-K filed June 2, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 84% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 25,942,042 for, 18,512 withheld.

FOR

FOR: 25,942,042WITHHOLD: 18,512

Largest asset managers voting on “Election of Class II Directors: Seth H.Z. Fischer” at Esperion Therapeutics, Inc., 2024-2025
Asset manager	For	Vote
WASATCH FUNDS TRUST	8,264,814	For
Vanguard	7,711,521	For
Fidelity	3,702,644	For
BlackRock	3,347,621	For
TIAA	794,539	For
Charles Schwab	431,527	For
Equitable	213,472	For
State Street	186,489	For
Invesco	162,539	For
ETFis Series Trust I	140,800	For
Lincoln Financial	140,100	For
Northern Trust	90,862	For
ProShares	89,094	For
Pacific Life	84,096	For
AIG/SunAmerica	79,571	For
Bridge Builder Trust	71,755	For
John Hancock	67,549	For
Voya	52,766	For
Brighthouse	43,205	For
Direxion Shares ETF Trust	40,608	For
Blackstone Alternative Investment Funds	40,100	For
Jacob Funds Inc.	31,497	For
SEI	31,100	For
DWS	29,757	For
Global X	29,749	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

3. TO APPROVE AN AMENDMENT TO THE ESPERION THERAPEUTICS, INC. 2022 STOCK OPTION AND INCENTIVE PLAN.

No official matchCOMPENSATION

99.9% of fund votes cast · no official result

FOR

Details: votes by 36 asset managers

The 36 asset managers below reported 25,957,750 for, 2,804 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 25,957,750AGAINST: 2,804

Largest asset managers voting on “TO APPROVE AN AMENDMENT TO THE ESPERION THERAPEUTICS, INC. 2022 STOCK OPTION AND INCENTIVE PLAN.” at Esperion Therapeutics, Inc., 2024-2025
Asset manager	For	Against	Vote
WASATCH FUNDS TRUST	8,264,814	0	For
Vanguard	7,711,521	0	For
Fidelity	3,702,644	0	For
BlackRock	3,347,621	0	For
TIAA	794,539	0	For
Charles Schwab	431,527	0	For
Equitable	213,472	0	For
State Street	186,462	27	For
Invesco	162,539	0	For
ETFis Series Trust I	140,800	0	For
Lincoln Financial	140,100	0	For
Northern Trust	90,862	0	For
ProShares	89,094	0	For
Pacific Life	84,096	0	For
AIG/SunAmerica	79,571	0	For
Bridge Builder Trust	71,755	0	For
John Hancock	67,549	0	For
Voya	52,766	0	For
Brighthouse	43,205	0	For
Direxion Shares ETF Trust	40,608	0	For
Blackstone Alternative Investment Funds	40,100	0	For
Jacob Funds Inc.	28,720	2,777	Mixed
SEI	31,100	0	For
DWS	29,757	0	For
Global X	29,749	0	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

4. To approve the non-binding advisory resolution on the compensation of our named executive officers.

No official match Fund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 3 wordings of this item as funds reported it.

90% Fund and manager reports combined; may count the same shares twice · no official result

FOR

Details: votes by 144 asset managers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 36 asset managers voting on “To approve the non-binding advisory resolution on the compensation of our named executive officers.” at Esperion Therapeutics, Inc., 2024-2025
Asset manager	For	Against	Vote
WASATCH FUNDS TRUST	8,264,814	0	For
Vanguard	7,711,521	0	For
Fidelity	3,702,644	0	For
BlackRock	3,347,621	0	For
TIAA	794,539	0	For
Charles Schwab	431,527	0	For
Equitable	213,472	0	For
State Street	186,489	0	For
Invesco	162,539	0	For
ETFis Series Trust I	140,800	0	For
Lincoln Financial	140,100	0	For
Northern Trust	90,862	0	For
ProShares	89,094	0	For
Pacific Life	84,096	0	For
AIG/SunAmerica	79,571	0	For
Bridge Builder Trust	71,755	0	For
John Hancock	67,549	0	For
Voya	52,766	0	For
Brighthouse	43,205	0	For
Direxion Shares ETF Trust	40,608	0	For
Blackstone Alternative Investment Funds	40,100	0	For
Jacob Funds Inc.	28,720	2,777	Mixed
SEI	0	31,100	Against
DWS	29,757	0	For
Global X	0	29,749	Against

Fund voting reports, all 36 managers: 25,866,060 for, 94,494 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 121 asset managers voting on “To approve the non-binding advisory resolution on the compensation of our named executive officers.” at Esperion Therapeutics, Inc., 2024-2025
Asset manager	For	Against	Abstain	Vote
WASATCH ADVISORS LP	9,771,807	0	0	For
Two Seas Capital LP	6,806,374	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	4,122,797	0	0	For
BlackRock	3,590,329	15,208	0	For
MARSHALL WACE, LLP	0	3,529,999	0	Against
Indaba Capital Management, L.P.	0	3,000,000	0	Against
State Street	2,983,715	966	0	For
Two Sigma	2,588,297	0	0	For
PenderFund Capital Management Ltd.	2,000,000	0	0	For
Citadel	910,069	0	0	For
Woodline Partners LP	906,810	0	0	For
Nuveen	802,702	0	0	For
Northern Trust	785,719	0	0	For
MELLON INVESTMENTS Corp	603,350	0	0	For
Connor, Clark & Lunn Investment Management Ltd.	579,171	0	0	For
Wellington	0	553,694	0	Against
Charles Schwab	431,527	0	0	For
DE Shaw	253,397	0	0	For
Invesco	240,309	0	0	For
DAVIDSON KEMPNER CAPITAL MANAGEMENT LP	0	0	222,482	Abstain
NJ State Employees Deferred Compensation Plan	195,125	0	0	For
Pentwater Capital Management LP	181,290	0	0	For
AllianceBernstein	159,260	0	0	For
T. Rowe Price	135,706	0	0	For
MACKENZIE FINANCIAL CORP	0	123,115	0	Against

Institutional-manager reports, all 121 managers: 38,982,681 for, 7,481,209 against, 222,482 abstained. Showing the 25 largest; see all in the interactive database.

5. Advisory Vote to Ratify Named Executive Officers' Compensation

No official matchCOMPENSATION

100% of fund votes cast · no official result

FOR

Details: votes by 2 asset managers

The 2 asset managers below reported 89,419 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 89,419

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at Esperion Therapeutics, Inc., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
JPMorgan	89,360	0	0	0	For
TD Waterhouse Canada Inc.	59	0	0	0	For

6. TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR…

No official matchAUDIT-RELATED

99.9% of fund votes cast · no official result

FOR

Details: description as filed, votes by 36 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

The 36 asset managers below reported 25,960,527 for, 27 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 25,960,527AGAINST: 27

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FI” at Esperion Therapeutics, Inc., 2024-2025
Asset manager	For	Against	Vote
WASATCH FUNDS TRUST	8,264,814	0	For
Vanguard	7,711,521	0	For
Fidelity	3,702,644	0	For
BlackRock	3,347,621	0	For
TIAA	794,539	0	For
Charles Schwab	431,527	0	For
Equitable	213,472	0	For
State Street	186,462	27	For
Invesco	162,539	0	For
ETFis Series Trust I	140,800	0	For
Lincoln Financial	140,100	0	For
Northern Trust	90,862	0	For
ProShares	89,094	0	For
Pacific Life	84,096	0	For
AIG/SunAmerica	79,571	0	For
Bridge Builder Trust	71,755	0	For
John Hancock	67,549	0	For
Voya	52,766	0	For
Brighthouse	43,205	0	For
Direxion Shares ETF Trust	40,608	0	For
Blackstone Alternative Investment Funds	40,100	0	For
Jacob Funds Inc.	31,497	0	For
SEI	31,100	0	For
DWS	29,757	0	For
Global X	29,749	0	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

Largest Esperion Therapeutics, Inc. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 189,460,293 shares outstanding at the time of that meeting.

Fund voting reports: top Esperion Therapeutics, Inc. shareholders by shares voted on “To approve the non-binding advisory resolution on the compensation of our named executive…”, 2024-2025
#	Asset manager	% of shares outstanding
1	WASATCH FUNDS TRUST	4.36%
2	Vanguard	4.07%
3	Fidelity	1.95%
4	BlackRock	1.77%
5	TIAA	0.42%
6	Charles Schwab	0.23%
7	Equitable	0.11%
8	State Street	0.10%
9	Invesco	0.09%
10	ETFis Series Trust I	0.07%

Institutional-manager reports: top Esperion Therapeutics, Inc. shareholders by shares voted on “To approve the non-binding advisory resolution on the compensation of our named executive…”, 2024-2025
#	Asset manager	% of shares outstanding
1	WASATCH ADVISORS LP	5.16%
2	Two Seas Capital LP	3.59%
3	GEODE CAPITAL MANAGEMENT, LLC	2.18%
4	BlackRock	1.90%
5	MARSHALL WACE, LLP	1.86%
6	Indaba Capital Management, L.P.	1.58%
7	State Street	1.58%
8	Two Sigma	1.37%
9	PenderFund Capital Management Ltd.	1.06%
10	Citadel	0.48%

Reported Esperion Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

Esperion Therapeutics, Inc. holdings and ownership disclosed for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Glazer Capital, LLC	11.07%	13G
BlackRock	7.65%	13F
Vanguard Group	6.06%	13F
BB Biotech AG	5.12%	13G
Morgan Stanley	3.48%	13F
State Street	2.40%	13F
Nuveen	1.65%	13F
Two Sigma	1.44%	13F
Citadel Advisors	1.37%	13F
JPMorgan Chase	1.01%	13F

Percentages above are of 189,460,293 shares outstanding, as reported by Esperion Therapeutics, Inc. on its Form 10-Q dated May 1, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Esperion Therapeutics, Inc.’s 10-Q dated May 1, 2024. This page is a static snapshot rebuilt weekly on October 25, 2026; a live search always shows the current data.

At Esperion Therapeutics, Inc.'s shareholder meeting held May 29, 2025, in the 2024-2025 proxy season, 146 asset managers reported how they voted in their SEC Form N-PX filings, covering 679 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Esperion Therapeutics, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve the non-binding advisory resolution on the compensation of our named executive… — the reporting funds and managers cast 90% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.

Esperion Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.